Skip to results

Last updated date

Last updated date

Area of interest

Area of interest

Type (1 selected)

Type

Guidance programme

Showing 101 to 150 of 1861

Published guidance, NICE advice and quality standards
TitleReference numberPublishedLast updated
Artificial metacarpophalangeal and interphalangeal joint replacement for end-stage arthritisIPG110
Artificial trapeziometacarpal joint replacement for end-stage osteoarthritisIPG111
Asciminib for treating chronic myeloid leukaemia after 2 or more tyrosine kinase inhibitorsTA813
Asfotase alfa for treating paediatric-onset hypophosphatasiaHST23
Assessing motility of the gastrointestinal tract using a wireless capsuleIPG502
Asthma: diagnosis, monitoring and chronic asthma managementNG80
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin geneHST22
Atezolizumab for adjuvant treatment of resected non-small-cell lung cancerTA823
Atezolizumab for treating locally advanced or metastatic non-small-cell lung cancer after chemotherapyTA520
Atezolizumab for treating locally advanced or metastatic urothelial carcinoma after platinum-containing chemotherapyTA525
Atezolizumab for untreated PD-L1-positive advanced urothelial cancer when cisplatin is unsuitableTA739
Atezolizumab in combination for treating metastatic non-squamous non-small-cell lung cancerTA584
Atezolizumab monotherapy for untreated advanced non-small-cell lung cancerTA705
Atezolizumab with bevacizumab for treating advanced or unresectable hepatocellular carcinomaTA666
Atezolizumab with carboplatin and etoposide for untreated extensive-stage small-cell lung cancerTA638
Atezolizumab with carboplatin and nab-paclitaxel for untreated advanced non-squamous non-small-cell lung cancer (terminated appraisal)TA618
Atezolizumab with nab-paclitaxel for untreated PD-L1-positive, locally advanced or metastatic, triple-negative breast cancerTA639
Atidarsagene autotemcel for treating metachromatic leukodystrophyHST18
Atogepant for preventing migraineTA973
Atopic eczema in under 12s: diagnosis and managementCG57
Atrial fibrillation and heart valve disease: self-monitoring coagulation status using point-of-care coagulometers (the CoaguChek XS system)DG14
Atrial fibrillation: diagnosis and managementNG196
Attention deficit hyperactivity disorder: diagnosis and managementNG87
Auditory brain stem implantsIPG108
Autism spectrum disorder in adults: diagnosis and managementCG142
Autism spectrum disorder in under 19s: recognition, referral and diagnosisCG128
Autism spectrum disorder in under 19s: support and managementCG170
Autologous blood injection for plantar fasciitisIPG437
Autologous blood injection for tendinopathyIPG438
Autologous chondrocyte implantation for treating symptomatic articular cartilage defects of the kneeTA477
Autologous chondrocyte implantation using chondrosphere for treating symptomatic articular cartilage defects of the kneeTA508
Autologous pancreatic islet cell transplantation for improved glycaemic control after pancreatectomyIPG274
Automated ankle brachial pressure index measurement devices to detect peripheral arterial disease in people with leg ulcersDG52
Automated percutaneous mechanical lumbar discectomyIPG141
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitisTA825
Avalglucosidase alfa for treating Pompe diseaseTA821
Avapritinib for treating unresectable or metastatic gastrointestinal stromal tumours (terminated appraisal)TA730
Avatrombopag for treating primary chronic immune thrombocytopeniaTA853
Avatrombopag for treating thrombocytopenia in people with chronic liver disease needing a planned invasive procedureTA626
Avelumab for maintenance treatment of locally advanced or metastatic urothelial cancer after platinum-based chemotherapyTA788
Avelumab for treating metastatic Merkel cell carcinomaTA517
Avelumab for untreated metastatic Merkel cell carcinomaTA691
Avelumab with axitinib for untreated advanced renal cell carcinomaTA645
Axicabtagene ciloleucel for treating diffuse large B-cell lymphoma and primary mediastinal large B-cell lymphoma after 2 or more systemic therapiesTA872
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after first-line chemoimmunotherapyTA895
Axicabtagene ciloleucel for treating relapsed or refractory follicular lymphomaTA894
Axitinib for treating advanced renal cell carcinoma after failure of prior systemic treatmentTA333
Axonics sacral neuromodulation system for treating refractory overactive bladderMTG50
Azacitidine for the treatment of myelodysplastic syndromes, chronic myelomonocytic leukaemia and acute myeloid leukaemiaTA218
Azacitidine for treating acute myeloid leukaemia with more than 30% bone marrow blastsTA399

Results per page

  1. 10
  2. 25
  3. 50
  4. All